1. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease. (3rd July 2017) Authors: Clark, L. A.; Whitmire, S.; Patton, S.; Clark, C.; Blanchette, C. M.; Howden, R. Journal: Journal of medical economics Issue: Volume 20:Number 7(2017) Page Start: 715 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗